Logotipo do repositório

Establishing a pediatric solid tumor PDX biobank for precision oncology research

dc.contributor.authorKido, Larissa Akemi
dc.contributor.authorMarusco, Milena Rodrigues
dc.contributor.authorda Silva, Ellen Aparecida
dc.contributor.authorDo Carmo, Laís
dc.contributor.authorBorges, Ana Beatriz Teodoro
dc.contributor.authorSilva, Felipe Luz Torres
dc.contributor.authorRuas, Juliana Silveira
dc.contributor.authorde Lima, Dieila Giomo
dc.contributor.authorFernandes, Larissa de Abreu [UNESP]
dc.contributor.authorDaiggi, Camila Maia Martin
dc.contributor.authorCardinalli, Izilda Aparecida
dc.contributor.authorEuzébio, Mayara Ferreira
dc.contributor.authorJotta, Patricia Yoshioka
dc.contributor.authorMaschietto, Mariana
dc.contributor.authorZenatti, Priscila Pini
dc.date.accessioned2026-07-16T17:29:08Z
dc.date.issued2025-08-13
dc.description.abstractDeveloping advanced preclinical models and targeted therapies is essential for reducing cancer-related deaths in children with solid tumors. Patient-derived xenografts (PDX) have the potential to replicate key elements of the original tumor, including morphology, genetic alterations, and microenvironment, making them valuable tools for studying tumor biology and drug response. We implanted 124 pediatric solid tumor samples, collected for 1 y, into NOD/SCID/IL2Rg (NSG) mice. Tumor fragments were placed subcutaneously, and the animals were monitored for up to 1 y. Histopathology, Short Tandem Repeat (STR) profiling, RT-PCR and/or RNA-sequencing were performed to confirm tumor identity and detect driver fusions. Fifty-five xenografts were successfully established (44.35% of implanted samples), representing 19 tumor types. Sarcomas, notably osteosarcoma, Ewing sarcoma, synovial sarcoma, and rhabdomyosarcoma, displayed first-generation engraftment rates above 55%. Central nervous system tumors had lower success, reflecting unique microenvironmental requirements. Histopathology and STR concordances were 85.45% and 81.1%, respectively, while 92.6% of sarcoma PDXs retained original fusion genes. Second-generation xenografts showed faster growth, suggesting adaptation to the murine host. Sporadic discrepancies, such as new fusions or lymphoproliferative expansions, indicated the need for ongoing molecular validation parallel to other techniques. A pediatric PDX biobank can effectively capture key tumor features while facilitating the study of therapeutic responses and tumor evolution. Our models confirm the feasibility of achieving stable histological and molecular profiles, offering a valuable resource for precision oncology research. Ultimately, these pediatric PDXs could accelerate the discovery of targeted therapy and significantly improve treatment outcomes.
dc.description.affiliationResearch Center, Boldrini Children’s Center, Campinas, Brazil
dc.description.affiliationFaculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
dc.description.affiliationBoldrini Children’s Center, Campinas, Brazil
dc.description.affiliationPostgraduate Program in Genetics and Molecular Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil
dc.description.affiliationInstitute of Biosciences, São Paulo State University, Botucatu, Brazil
dc.description.affiliationUnespInstitute of Biosciences, São Paulo State University, Botucatu, Brazil
dc.identifierhttps://app.dimensions.ai/details/publication/pub.1191685964
dc.identifier.dimensionspub.1191685964
dc.identifier.doi10.1080/15384047.2025.2541974
dc.identifier.issn1538-4047
dc.identifier.issn1555-8576
dc.identifier.orcid0000-0002-3653-8035
dc.identifier.orcid0000-0003-3321-7487
dc.identifier.orcid0000-0003-4292-0027
dc.identifier.orcid0000-0002-5967-5235
dc.identifier.orcid0000-0002-5163-6047
dc.identifier.orcid0000-0002-7329-3970
dc.identifier.orcid0000-0003-2627-2576
dc.identifier.orcid0000-0001-9820-8210
dc.identifier.orcid0000-0003-2589-3186
dc.identifier.orcid0000-0002-8662-7458
dc.identifier.pmcidPMC12351738
dc.identifier.pmid40801203
dc.identifier.urihttps://hdl.handle.net/11449/328002
dc.publisherTaylor & Francis
dc.relation.ispartofCancer Biology & Therapy; n. 1; v. 26; p. 2541974
dc.rights.accessRightsAcesso abertopt
dc.rights.sourceRightsoa_all
dc.rights.sourceRightsgold
dc.sourceDimensions
dc.titleEstablishing a pediatric solid tumor PDX biobank for precision oncology research
dc.typeArtigopt
dspace.entity.typePublication
relation.isOrgUnitOfPublicationab63624f-c491-4ac7-bd2c-767f17ac838d
relation.isOrgUnitOfPublication.latestForDiscoveryab63624f-c491-4ac7-bd2c-767f17ac838d
unesp.campusUniversidade Estadual Paulista (UNESP), Instituto de Biociências, Botucatupt

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
KCBT_26_2541974.pdf
Tamanho:
4,71 MB
Formato:
Adobe Portable Document Format